Farmas USA

REGN +6% en premarket por el fail de OPTH. A ver si tira hacia arriba del IBB

juas, pero que pronto las vendi!!!

REGN

Gracias por recordarlo, a mi se me habia pasado por alto.

AKAO
Achaogen's plazomicin successful in late-stage studies; U.S. marketing application on tap for H2 2017; shares up 22% premarket
http://www.seekingalpha.com/news/3229914

Desbandada en Alexion...

Alexion Pharma (ALXN) CEO Hallal Resigns for Personal Reasons; CFO Sinha Leaves to Pursue Other Opportunities
http://www.streetinsider.com/Corporate+News/Alexion+Pharma+(ALXN)+CEO+Hallal+Resigns%3B+CFO+Leaves/12332108.html

Por una vez comparto la opinión del bastardo de que podrían ser más claros en los motivos...
https://twitter.com/adamfeuerstein/status/808292447939919876

ALXN

ADXS

Advaxis' (ADXS) Lm Technology Focus at International Congress on Immunotherapies in Cancer

the preclinical ADXS-HOT program, which will utilize the company’s Lm Technology to develop constructs that will target tumor driver genes that carry mutations occurring in hotspots. These hotspots, often called public mutations, are commonly observed in multiple patients’ tumors and found in multiple tumor types. With ADXS-HOT, Advaxis will be developing a library of off-the-shelf agents that can be administered to patients with cancer who test positive for biomarkers that detect common genetic mutations. These constructs will be available for immediate use, thereby reducing the turnaround time between a patient’s biopsy and the start of treatment. The company will initially focus on constructs targeting several of the most critical mutations in tumor driver genes associated with many cancers and plans to file an IND for ADXS-HOT in the second half of 2017.

Earlier this year, Advaxis announced a global collaboration with Amgen to develop its MINE™ (My Immunotherapy Neo-Epitopes) program and ADXS-NEO, which is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in each individual patient's tumor by using parallel DNA sequencing. Unlike ADXS-HOT for public hotspots, ADXS-NEO is directed at patient-specific mutations.

http://www.streetinsider.com/Corporate+News/Advaxis+%28ADXS%29+Lm+Technology+Focus+at+International+Congress+on+Immunotherapies+in+Cancer/12332383.html?si_client=intbro

Llama a Chuck..

OPHT

Alguien puede poner el pre de HZNP? No me sale...